DXR Stock Analysis
DX
Avoid
Based on Eyestock quantitative analysis, DXR`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. The company is headquartered in New York City, New York. The firm is focused on blood volume measurement. The firm has developed and marketed the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the food and drug administration (FDA) to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a broad range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. The company has ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the National Institutes of Health (NIH) and is under contract developing analyzers.